Overview of Tissue Engineering
Tissue engineeringaims to create artificial tissue from biomaterials, specific cells, and growth factors. These engineered tissue constructs have far-…
Tissue Engineering is a field of regenerative medicine that uses cells, biomaterials, and biologically active molecules to create, repair, or replace tissue. Natural tissue consists of a structural component, the extracellular matrix, or ECM, and the tissue-specific cells that inhabit it. Engineered tissue aims to resemble natural tissue as closely as possible, using natural or engineered structural components and tissue-specific cells. This video will introduce the field of tissue-engineering, demonstrate some common techniques and challenges in the field, and introduce some applications of this technology.
First, let's take a look at the typical components of engineered tissue. The tissue is formed by first creating a scaffold using a biomaterial. The tissue scaffold is intended to provide structure and mimic the natural ECM. The tissue scaffold can take many different morphologies, such as a fiber mat, or a hydrogel, depending on the desired type of tissue. In any case, the biomaterial used must promote cell adhesion and desirable cell interaction. Alternatively, a decellularized scaffold from a donor organ can also be used to provide structure to the new tissue. The next component is the cells. All tissues utilize living cells, which define the tissue type. For example, fibroblasts are used to make skin, and chondrocytes are used to make cartilage. The cells used in engineered tissue can come from several sources. Primary cells are extracted from native tissue, which requires that the native tissue is minced and digested with an enzyme to release the cells. Alternatively, secondary cells, which are available from a cell bank, can be used. However, these cells are not patient-specific and can cause rejection. Finally, stem cells can also be used, which are undifferentiated cells that are able to give rise to different forms of specialized cells, or replicate themselves. To create the tissue, the selected cells are seeded on the tissue scaffold, along with necessary growth factors to encourage tissue formation. The seeded scaffolds are then allowed to grow in a static culture. Alternatively, specialized tissue culture reactors can be used to seed and grow the engineered tissue.
Now that the components of engineered tissue have been introduced, let's take a look at some common methods used in the field. Fabrication of the tissue scaffold can be the most critical factor in determining the tissue's mechanical properties. A popular scaffold morphology is the electrospun scaffold, which is mat of micro-scale fibers. Electrospinning is done by applying a voltage between a collection plate and the tip of a syringe containing the biomaterial. This creates microfibers, which are allowed to collect until the mat reaches the necessary requirements for the scaffold. It must have interconnected micropores to allow for cells and nutrients to migrate in; adequate surface area to promote cell adhesion; and mechanical properties that match native tissue. Next, a key technique used to grow tissue is a tissue culture reactor. Tissue scaffolds are often seeded with cells through droplet or submersion techniques, and allowed to grow in stagnant culture. However, natural tissue, such as blood vessels, grow under mechanical stimulation. Tissue culture reactors aim to mimic physiological conditions, such as the pulsatile flow in arteries, in order to influence the behavior and growth of endothelial and muscle cells in the artery.
There are many challenges faced in this field, however. The main limitation of in-vitro engineered tissue is the lack of blood-vessel systems. Natural tissues possess vascularization, which provides nutrients and removes waste. However, engineered tissue relies heavily on diffusion, which limits nutrients supply and tissue size. One strategy for vascularization is focused on the use of synthetic scaffolds with built-in vasculature, which could aid in delivering nutrients to the tissue. Though the benefits of engineered tissue are far-reaching, it is difficult to produce tissue on a large enough scale for clinical use. For implantation, cells must first be harvested from the patient and then expanded and cultured on a scaffold. This would require separate cell culture systems for each patient. In addition to the significant amount of time required for these steps, the regulatory challenges and high costs make this difficult to implement broadly at this point.
Now that you've seen some of the current methods and challenges of tissue engineering, let's take a look at some applications of the technology. Tissue engineering can be used in chronic wound or burn healing. One method is to use a tissue scaffold containing growth factors but no cells. The decellularized matrix promotes the migration of cells and encourages tissue growth. Alternatively, for deep wounds, a matrix containing cells can be used, which integrates into the host's tissue. Eventually, researchers aim to be able to fully replace damaged organs. Currently, this is approached using organ culture. First, the donor organ, such as a lung in this case, is decellularized and its native structure maintained, then the lung is recellularized with cells from the patient. This would limit rejection and the need for a donor match.
You've just watched Jove's Overview of Tissue Engineering. You should now be familiar with some basic concepts and methods in the field, as well as some key challenges and applications. Thanks for watching.
Tissue Engineering is a field of regenerative medicine that uses cells, biomaterials, and biologically active molecules to create, repair, or replace tissue. Natural tissue consists of a structural component, the extracellular matrix, or ECM, and the tissue-specific cells that inhabit it. Engineered tissue aims to resemble natural tissue as closely as possible, using natural or engineered structural components and tissue-specific cells. This video will introduce the field of tissue-engineering, demonstrate some common techniques and challenges in the field, and introduce some applications of this technology.
First, let's take a look at the typical components of engineered tissue. The tissue is formed by first creating a scaffold using a biomaterial. The tissue scaffold is intended to provide structure and mimic the natural ECM. The tissue scaffold can take many different morphologies, such as a fiber mat, or a hydrogel, depending on the desired type of tissue. In any case, the biomaterial used must promote cell adhesion and desirable cell interaction. Alternatively, a decellularized scaffold from a donor organ can also be used to provide structure to the new tissue. The next component is the cells. All tissues utilize living cells, which define the tissue type. For example, fibroblasts are used to make skin, and chondrocytes are used to make cartilage. The cells used in engineered tissue can come from several sources. Primary cells are extracted from native tissue, which requires that the native tissue is minced and digested with an enzyme to release the cells. Alternatively, secondary cells, which are available from a cell bank, can be used. However, these cells are not patient-specific and can cause rejection. Finally, stem cells can also be used, which are undifferentiated cells that are able to give rise to different forms of specialized cells, or replicate themselves. To create the tissue, the selected cells are seeded on the tissue scaffold, along with necessary growth factors to encourage tissue formation. The seeded scaffolds are then allowed to grow in a static culture. Alternatively, specialized tissue culture reactors can be used to seed and grow the engineered tissue.
Now that the components of engineered tissue have been introduced, let's take a look at some common methods used in the field. Fabrication of the tissue scaffold can be the most critical factor in determining the tissue's mechanical properties. A popular scaffold morphology is the electrospun scaffold, which is mat of micro-scale fibers. Electrospinning is done by applying a voltage between a collection plate and the tip of a syringe containing the biomaterial. This creates microfibers, which are allowed to collect until the mat reaches the necessary requirements for the scaffold. It must have interconnected micropores to allow for cells and nutrients to migrate in; adequate surface area to promote cell adhesion; and mechanical properties that match native tissue. Next, a key technique used to grow tissue is a tissue culture reactor. Tissue scaffolds are often seeded with cells through droplet or submersion techniques, and allowed to grow in stagnant culture. However, natural tissue, such as blood vessels, grow under mechanical stimulation. Tissue culture reactors aim to mimic physiological conditions, such as the pulsatile flow in arteries, in order to influence the behavior and growth of endothelial and muscle cells in the artery.
There are many challenges faced in this field, however. The main limitation of in-vitro engineered tissue is the lack of blood-vessel systems. Natural tissues possess vascularization, which provides nutrients and removes waste. However, engineered tissue relies heavily on diffusion, which limits nutrients supply and tissue size. One strategy for vascularization is focused on the use of synthetic scaffolds with built-in vasculature, which could aid in delivering nutrients to the tissue. Though the benefits of engineered tissue are far-reaching, it is difficult to produce tissue on a large enough scale for clinical use. For implantation, cells must first be harvested from the patient and then expanded and cultured on a scaffold. This would require separate cell culture systems for each patient. In addition to the significant amount of time required for these steps, the regulatory challenges and high costs make this difficult to implement broadly at this point.
Now that you've seen some of the current methods and challenges of tissue engineering, let's take a look at some applications of the technology. Tissue engineering can be used in chronic wound or burn healing. One method is to use a tissue scaffold containing growth factors but no cells. The decellularized matrix promotes the migration of cells and encourages tissue growth. Alternatively, for deep wounds, a matrix containing cells can be used, which integrates into the host's tissue. Eventually, researchers aim to be able to fully replace damaged organs. Currently, this is approached using organ culture. First, the donor organ, such as a lung in this case, is decellularized and its native structure maintained, then the lung is recellularized with cells from the patient. This would limit rejection and the need for a donor match.
You've just watched Jove's Overview of Tissue Engineering. You should now be familiar with some basic concepts and methods in the field, as well as some key challenges and applications. Thanks for watching.
View the full transcript and gain access to JoVE Science Education videos
Q1: What are the main components of engineered tissue?
Engineered tissue consists of three key components: a biomaterial scaffold that mimics the natural extracellular matrix, tissue-specific cells that define the tissue type, and growth factors that encourage tissue formation. The scaffold provides structure and promotes cell adhesion, while cells such as fibroblasts for skin or chondrocytes for cartilage give the tissue its functional identity.
Q2: How does electrospinning create tissue scaffolds?
Electrospinning applies voltage between a collection plate and a syringe tip containing biomaterial, creating micro-scale fibers that collect into a mat. The resulting scaffold must have interconnected micropores for cell and nutrient migration, adequate surface area for cell adhesion, and mechanical properties matching native tissue. This technique produces fiber mats suitable for various tissue types.
Q3: What sources of cells can be used in tissue engineering?
Three cell sources are available for tissue engineering: primary cells extracted from native tissue through enzymatic digestion, secondary cells from cell banks that are readily available but may cause rejection, and stem cells that are undifferentiated and can differentiate into specialized cell types or self-replicate. Each source has distinct advantages and limitations for clinical applications.
Q4: Why is vascularization a major challenge in tissue engineering?
Natural tissues possess vascularization that delivers nutrients and removes waste, but engineered tissue relies on diffusion, which severely limits nutrient supply and restricts tissue size. This limitation prevents the creation of large, thick tissues needed for organ replacement. Researchers are developing synthetic scaffolds with built-in vasculature to address this critical challenge.
Q5: How do tissue culture reactors improve engineered tissue growth?
Tissue culture reactors mimic physiological conditions such as pulsatile flow found in arteries, providing mechanical stimulation that influences cell behavior and growth. Unlike static culture, these specialized systems promote development of endothelial and muscle cells by replicating the dynamic environment of natural tissue, leading to more functional engineered constructs.
Q6: What are the clinical applications of tissue engineering?
Tissue engineering treats chronic wounds and burns using decellularized matrices with growth factors to promote cell migration, or cell-containing matrices that integrate into host tissue. Researchers also pursue organ replacement through organ culture, where donor organs are decellularized and recellularized with patient cells, reducing rejection risk and eliminating donor matching requirements.
Q7: What barriers prevent tissue-engineered products from reaching clinical use at scale?
Scaling tissue engineering for clinical use requires separate cell culture systems for each patient, involving time-intensive cell harvesting, expansion, and culturing on scaffolds. Regulatory challenges and high production costs further complicate broad implementation. These factors make it difficult to produce tissue in quantities sufficient for widespread clinical deployment.